DMT is rapidly acting and effects are typically observed around minutes after consumption and last around minutes. Despite its short-lived effects, DMT is known as one of the most powerful psychedelic drugs. The subjective effects of DMT can often be meaningful but will vary with dosage.
These include:. DMT is associated with low toxicity and is easily metabolised by the body. However, there are physiological implications and associated risks to be aware of. These include elevated blood pressure and increased heart rate, which is particularly risky for those with heart conditions. The impaired cognitive and motor function poses a personal safety risk and presents further reason for DMT to be consumed in a safe environment with a sober sitter.
It should be noted that at high doses there are some reports of seizures , respiratory effects and comas. DMT, when consumed in the form of ayahuasca, has a long history of traditional medicinal use for numerous indigenous tribes across the Lower and Upper Amazon.
The therapeutic potential of ayahuasca as a therapy tool in psychotherapy has generated significant clinical interest and several clinical trials have reported beneficial effects in the treatment of addiction and depression.
The growing mainstream appreciation for the therapeutic potential of ayahuasca DMT-containing brew and other classical psychedelics has generated increased scientific interest as to whether DMT has therapeutic potential. Scientific studies have demonstrated similarities between DMT and psilocybin, whereby DMT is able to produce a comparable mystical experience to that of psilocybin. It is suggested that psilocybin alters brain activity and enables the brain to reset.
Therefore, recent evidence that DMT causes changes in human brain activity could be of therapeutic value. These similarities suggest that DMT may have a similar therapeutic potential to psilocybin in treating psychiatric disorders such as depression and anxiety. DMT induces a particularly potent psychedelic experience consisting of intense visual alterations and hallucinations, alongside alterations in emotion and mood. The intensity of the trip can be emotionally challenging for some people, inducing states of panic, anxiety and paranoia.
For some people DMT produces an out-of-body experience or depersonalisation, which can be an overwhelming experience. A sober sitter is an important safety measure to mitigate psychological harm. Similar to other psychedelics, history of mental health illness such as schizophrenia, psychosis and bipolar disorder may increase the likelihood of an unpleasant experience and there is the risk DMT may exacerbate these conditions.
However, there is still a limited understanding of the risks associated with the use of psychedelics in those with pre-existing mental health conditions. This can result in a potentially life-threatening condition called serotonin syndrome. This includes some antidepressants and selective serotonin reuptake inhibitors SSRIs. DMT should not be mixed with alcohol or other drugs and an understanding of the effects and mechanism can provide insight into the risks associated with mixing it with other drugs.
Key drug combinations to avoid are listed below:. DMT, along with other classical psychedelics, is not addictive. However, tolerance can develop with frequent use, whereby a higher dose is required to achieve the same effect. DMT is a powerful psychedelic drug that can produce a rapid and intense hallucinogenic experience. Informed harm reduction advice can help to mitigate some of the associated risks.
It is important that you fully educate yourself on the health risks and drug interactions associated with DMT. It is important to ensure that the correct form and method of consumption is used, as well as a suitable dose. The particularly intense nature of DMT makes it important that sufficient preparation is done. This includes an awareness of the psychological and physical effects that DMT may induce. This can have a significant effect on the experience of the trip and therefore it is advised that DMT is only consumed when a person is in a positive and stable state of mind.
Data were subsequently developed illustrating pathways for their endogenous synthesis in mammalian species, including humans. However, there has yet to be any clear-cut or repeatable correlation of the presence or level of DMT in peripheral body fluids with any psychiatric diagnosis. Numerous studies subsequently demonstrated the biosynthesis of DMT in mammalian tissue preparations in vitro and in vivo Saavedra and Axelrod, ; Saavedra et al.
In , Saavedra et al. The highest enzyme activity in human brain was found in the subcortical layers of the fronto-parietal and temporal lobes and the cortical layers of the frontal parietal lobe. This suggested that INMT may exist in several isoenzyme forms between species and possibly even within the same animal, each having different Km's and substrate affinities.
INMT activity has subsequently been described in a variety of tissues and species. There have also been several reports of an endogenous inhibitor of INMT in vivo that may help regulate its activity and, thus, DMT biosynthesis Wyatt et al.
Pathways for the biosynthesis and metabolism of DMT, 1. As a historical and research note regarding DMT, there was initial confusion and misidentification of the products formed when using 5-methyltetrahydrofolate 5-MTHF as the methyl source in INMT studies due to formation of indole-ethylamine condensation products with formaldehyde tetrahydro-beta-carbolines Barchas et al. Relatively elevated levels of INMT activity have been found in the placenta from a variety of species, including humans Thompson et al.
INMT activity in rabbit lung was reported to be elevated in the fetus and to increase rapidly after birth, peaking at 15 days of age. It then declined to mature levels and remained constant through life Lin et al. In this regard, Beaton and Morris have examined the ontogeny of DMT biosynthesis in the brain of neonatal rats and rats of various ages. Using gas chromatography-mass spectrometry with isotope dilution for their analyses, DMT was detected in the brain of neonatal rats from birth.
There has yet to be any follow-on research as to the significance of this change in DMT concentrations during rat brain neurodevelopment or correlation with possible changes of INMT activity in other developing tissues, specifically during days 12— Nonetheless, these findings correlate well with the Lin et al.
There is a significant literature concerning INMT, particularly in peripheral tissues. INMT and its gene have been sequenced Thompson et al. These data became the foundation for several hypotheses that any neuropharmacological effects of endogenous DMT must lie in its formation in the periphery and its subsequent transport into the brain. This idea was strengthened by the fact that DMT has been shown to be readily, and perhaps actively, transported into the brain Cozzi et al.
However, the data concerning the apparent absence of INMT in brain would appear to be in conflict with the many earlier studies that demonstrated both in vivo and in vitro biosynthesis of DMT in the brain. Indeed, several studies had identified INMT activity or the enzyme itself in the central nervous system CNS including the medulla, the amygdala, uncus, and frontal cortex Morgan and Mandell, , the fronto-parietal and temporal lobes Saavedra et al.
Thus, in , Cozzi et al. INMT immunoreactivity in spinal cord was found to be localized in ventral horn motoneurons. Further, intense INMT immunoreactivity was detected in retinal ganglion neurons and at synapses in the inner and outer plexiform layers Cozzi et al.
In , Mavlyutov et al. It was proposed that the close association of INMT and sigma-1 receptors suggests that DMT is synthesized locally to effectively activate sigma-1 in motoneurons. It has been further proposed that DMT is an endogenous sigma-1 receptor regulator Fontanilla et al.
Taking these newer data together with historical in vitro and in vivo results regarding INMT enzyme activity in the brain and CNS, it is now clear that the work of Thompson and Weinshilboum is not the final word on DMT biosynthesis in the brain. Considering that tryptamine formation, itself a trace biogenic amine, is essential for the formation of DMT and given its own rapid metabolism by monoamine oxidase MAO as well, demonstrating its availability for the biosynthesis of DMT is also relevant to a complete elucidation of the overall pathway.
With demonstration of colocalization of the necessary biosynthetic machinery in the brain, both AADC and INMT, mechanisms for a rapid biochemical response to signaling and DMT formation may be shown to exist.
Furthermore, the demonstration of mechanisms for the protection, storage, release and reuptake of DMT would demonstrate that higher concentrations of DMT could be reached in the synaptic cleft and at neuronal receptors than would have to occur from, based on previous thought, formation and transport from the periphery.
We should not rule out the possibility that the biosynthesis and transport of DMT can and does occur from the periphery, however. Peripheral DMT, especially if synthesized in tissues that bypass liver metabolism on first pass, may also serve as a signaling compound from the periphery to the brain.
Such signaling may occur in maintaining homeostasis or in response to extreme changes in physiology. A thorough re-examination of possible peripheral DMT biosynthesis is needed. Thus, much of the INMT in the periphery may be involved to a greater degree with methylation of other substances than TA alone. Failure to demonstrate colocalization of INMT and AADC in the periphery would alter, to some degree, the focus of studies of peripheral synthesis and detection for understanding the role of endogenous DMT.
These data are underscored by the findings of Barker et al. Clearly, further research into the biosynthesis and role of DMT in the pineal is needed, as is a further assessment of our current knowledge of pineal function. We will also need to examine protein and gene arrays to determine the factors that assist or work in concert with the up and down regulation of the INMT system in brain and how it responds to selected physiological changes.
Such analyses will be essential in examining the possible role of DMT biosynthesis in changing biochemical and physiological events. It would also be of interest to better understand the possible role of DMT in neurodevelopment as suggested by the work of Beaton and Morris and Lin et al.
While DMT appears to clearly be biosynthesized in the pineal, mechanisms for its biosynthesis and release may exist in other brain areas as well and research into these other possibilities will also need to proceed. The metabolism of DMT has been thoroughly studied, with a great deal of newer data being provided from studies of ayahuasca administration McIlhenny et al.
All of the in vivo metabolism studies have shown that exogenously administered IV, IM, smoking, etc. For example, 0. DMT administered in this manner reached a peak concentration in blood within 10—15 min and was below the limits of detection within 1 h.
It was estimated that only 1. Due to rapid metabolism in the periphery, DMT is not orally active, being converted to inactive metabolites before sufficient penetration to the brain can occur low bioavailability.
DMT is pharmacologically active following administration by injection intravenous or intramuscular routes or smoking vaporization and inhalation , pathways which can avoid first-pass metabolism by the liver to some degree Riba et al. The time to onset of effects is rapid seconds to minutes by these routes and short lived 15—60 min depending on dose and route. However, these latter metabolites have yet to be identified in vivo.
Sitaram and McLeod, ; Barker et al. All of these factors need to be examined. Given that peripherally administered DMT, at what must be considered as much higher doses than would be expected to occur naturally in the entire organism, is rapidly metabolized and cleared, measuring endogenous DMT alone in an attempt to assess its role and function is probably doomed to failure. This is particularly true if endogenous DMT is mainly produced, stored and metabolized in discreet brain areas and that DMT and its metabolites so produced never attain measurable levels in peripheral fluids.
These compounds have been variously reported in tissue, blood and urine samples. It is not unreasonable to question whether measurement of DMT and its metabolites, and thus the role and function of endogenous DMT, can be understood by simply trying to measure these compounds in the periphery.
Peripheral measurements may not be the way to determine the central role of DMT and DMT produced in the brain may never be available for measurement in the periphery. Nonetheless, additional studies should determine if there is validity in such measurements and examine possible circadian, ultradian or diurnal variations in DMT synthesis as well as the changes that may occur due to alterations in other physiological parameters.
Barker et al. In total, the 69 studies examined DMT in thousands of subjects. The reasons for this conclusion were: 1 Based on current analytical requirements for unequivocal structure identification, it is highly probable that many of these studies misidentified the target analyte. Nevertheless, it was also concluded that, particularly where mass spectral evidence was provided, DMT and HDMT are endogenous and can often be successfully measured in human body fluids.
There was no mass spectral data demonstrating detection of MDMT in blood or urine. In conducting studies to determine the natural occurrence of a compound as being endogenous, it is also necessary to eliminate other possible dietary or environmental sources.
Of the 69 studies reviewed, many addressed the possible source of DMT as being from diet or gut bacteria Barker et al. Of those conducted, it was determined that neither was a source but additional research in this area using more modern technology and a more standard diet across studies is a necessity.
There have also been only a few efforts to examine the many variables that may influence the levels of these compounds, such as circadian or diurnal variations, sleep stages and gender-age-related differences. Indeed, most of the studies collected only a single time point or were from 24 h collections urine.
Such infrequent sampling makes it impossible to assess central DMT production from peripheral measurements and suggests, perhaps incorrectly, that DMT only appears intermittently or not at all. In terms of pursuing future research on the presence of the endogenous indolealkylethylamines, further studies are necessary to determine whether MDMT actually exists in humans. Future analyses to determine endogenous N, N-dimethyl-indolethylamines should also include a search for their major metabolites.
The methodology applied in such analyses must include rigorous validated protocols for sample collection, storage, extraction and analyte stability and appropriate criteria for unequivocal detection and confirmation of the analytes using validated methods.
Modern exact-mass liquid chromatography-mass spectrometry instrumentation should be the analytical method of choice. In fact, there have been no efforts to quantify the actual levels of endogenous DMT and its metabolites in human brain and only a few have attempted to address the issue in rats.
As noted, no circadian studies of DMT production or release from the pineal as a function of time have ever been conducted. This study's information is unfortunately quite limited in terms of sample number and did not address extraction recoveries, method validation or brain distribution of DMT.
The highest levels were Values for other days ranged from undetected limit of detection of 1. Since pooled whole brain 2. The data necessarily expressed the DMT concentration as if it was homogeneously distributed. Rats were also sacrificed at constant times during the study and no accounting was made for possible circadian or ultradian variations.
Given these facts, any speculation that attempts to dismiss the relevance of DMT in vivo because the concentrations in brain are too low Nichols, necessarily ignores the fact that data concerning the actual levels of DMT in brain, particularly humans and levels that may be observed in different brain areas, simply does not exist.
While more research into the brain concentrations and distribution of DMT is obviously warranted, it is possible, as with many other substances, that it may only be found in specific brain areas or cell types. For example, the pineal gland of an adult rat weighs between 0. If all of the DMT found, on average, at day 17 While converting g to ml regarding tissue is by no means exact, the point to be made is that DMT in brain could have significant concentrations in discrete brain areas and exist in sufficient concentrations in such areas to readily affect various receptors and neuronal functions.
Lower concentrations could occur in other brain areas as well with their concentrations being enhanced by mechanisms for DMT uptake and vesicular storage. What is obvious from these speculative calculations is the fact that more research into DMT brain distribution and concentrations is needed, recognizing its rapid metabolism and possible sequestration.
As with measurements in other matrices, well validated and sensitive methods for such quantitative analyses will be required. There is a significant literature correlating the binding affinity of DMT and related hallucinogens for the 5HT2A receptor and its subset of receptors with other hallucinogens and their subsequent behavioral effects Glennon et al.
However, DMT has been shown to interact with a variety of ionotropic and metabotropic receptors. While the subjective behavioral effects of exogenously administered DMT appear to be primarily acting via 5-HT2A receptors, the interaction of other receptors, such as other serotonergic and glutaminergic receptors, may also play a synergistic and confounding role. Indeed, the activation of frontocortical glutamate receptors, secondary to serotonin 5-HT2A receptor-mediated glutamate release, appears to be a controlling mechanism of serotonergic hallucinogens dos Santos et al.
However, although this type of receptor research is quite mature, these findings have yet to define and accurately correlate what makes a compound hallucinogenic vs. For example, Keiser et al. Nonetheless, it was observed that DMT was not only a potent partial agonist at 5-HT2A but also that the DMT-induced head twitch response, a common measure of hallucinogenic activity, occurred only in wild-type mice but not in 5-HT2A knockout mice.
Furthermore, DMT-enhanced inositol trisphosphate production has been shown to persist even in the presence of the 5-HT2A antagonist ketanserin Deliganis et al. Of interest is the finding of Urban et al. Thus, certain compounds may selectively activate a specific subset of effectors producing a functional selectivity that complicates the interpretation of observed psychopharmacological or biochemical effects.
In this regard, Carhart-Harris and Nutt have recently offered a novel bipartite model of serotonin neurotransmission involving co-modulation of the 5-HT1A and 5-HT2A receptors. This bipartite model purports to explain how different serotonergic drugs including psychedelics modulate the serotonergic system in different ways to achieve their observed pharmacology. Clearly the 5-HT2A receptor is involved in the mode of action of DMT and other hallucinogens, but is it also clear that this is not the sole receptor on which we should rely for an overall explanation Ray, ; Halberstadt and Geyer, ; Nichols, , Despite the failure of serotonin receptor binding theory to completely explain hallucinogenic activity, these observations support the 5-HT2A receptor as being a possible primary target for DMT's hallucinogenic effects Keiser et al.
In examining the possible complex interaction of multiple systems that may be necessary to explain the effects of compounds such as DMT, attention has also turned toward additional possible binding sites. There has yet to be sufficient research of TAAR to determine what role, if any, this class of receptors plays in the pharmacology or endogenous function of DMT.
Thus, the research to date regarding the role of TAAR receptors suffers from the same lack of explanation for the mode of action of the hallucinogens as the 5-HT2A but may comprise a piece of what is obviously a complex set of interactions. Another receptor family has also been implicated; the sigma-1 receptor.
One of the possible roles of the sigma-1 receptor appears to be to act as an intracellular chaperone between the endoplasmic reticulum ER and mitochondria. In this role, it is involved in the transmission of ER stress to the nucleus Carbonaro and Gatch, This process would be expected to result in the enhanced production of anti-stress and antioxidant proteins, with the activation of sigma-1 mitigating the possible damage done by hypoxia or oxidative stress Szabo et al.
Using in vitro cultured human cortical neurons derived from induced pluripotent stem cells , monocyte-derived macrophages, and dendritic cells, Szabo et al. Such a mechanism has relevance to stroke, myocardial infarct or similar arterial occlusive disorders, cardiac arrest, and perinatal asphyxia, all conditions associated with hypoxic consequences Carbonaro and Gatch, Szabo et al.
These sigma-1 associated effects may also be related to findings that DMT affects the rate of genetic transcription associated with synaptic plasticity O'Donovan et al.
The sigma-1 receptor has been implicated in several neurobiological disorders and conditions and is found widely distributed though out the body, including in the CNS.
However, both hallucinogens and non-hallucinogens bind to sigma-1 receptors, again complicating an attribution to this receptor as the primary site of DMT's action. INMT has been shown to be co-localized with sigma-1 receptors in C-terminals of motor neurons Mavlyutov et al. It has also been observed that sigma-1 receptor agonists are potentially neuroprotective Frecska et al. DMT has been shown to reduce neuronal inflammation via the sigma-1 receptor Szabo et al.
Sigma-1 receptors can also influence cell survival and proliferation Collina et al. With respect to the ontogeny of DMT, Lin et al. It is possible that DMT-mediated sigma-1 receptor activity is also increased during this period to induce neuronal changes in newborns.
Several selective sigma-1 receptor agonists have been shown to be protective against excitotoxic perinatal brain injury Griesmaier et al. In addition, it has been suggested that adequate expression of placental INMT may be necessary for pregnancy success Nuno-Ayala et al. Molecular biological studies of DMT's effects on these receptors and DMT's effects on their up-or-down regulation will also prove informative. This understanding may also lead to new therapeutic applications for regulating and altering endogenous DMT levels and function, providing new avenues for understanding hallucinogen pharmacology and their possible therapeutic use.
The data suggest that the 5-HT2A receptor is only part of the story. A more integrative mechanism to explain hallucinogenic activity, as suggested by Urban et al. Perhaps it is their interaction with many receptors and their complex functional connectivity that produces the observed effects Ray, ; Halberstadt and Geyer, Indeed, the data suggest that DMT is both endogenous and possesses the properties of a neurotransmitter see below.
Studies have clearly shown that it binds with respectable affinity to the 5-HT2A receptor as well as other members of the serotonin family of receptors and elicits biochemical and physiological activity that can be correlated, to some degree, with such binding. These data support the idea that it is, therefore, an endogenous ligand for such receptors and intrinsically involved in serotonergic function. This being the case, there is already a significant body of work regarding DMT's binding and effects, especially relative to effects on serotonin, acting as a serotonergic modulator.
Additional work in this area, while acknowledging DMT as an endogenous ligand, will prove essential. It is also unlikely that DMT acts alone in exerting it effects. Changes in relevant metabolomic and array profiles following DMT administration will further add to our understanding of its endogenous role.
Intramuscular effects of DMT at a reported dose of 0. The IM effects are usually less intense than intravenous or inhalation-of-vapor routes of administration. The subjective effects of DMT from ayahuasca administration 0. The prolongation of effect is attributed to the MAOI effects of the constituent harmala alkaloids. Riba et al. As expected, oral ingestion of pure DMT produced no psychotropic effects.
Vaporized DMT was found to be quite psychoactive. Commonly used doses for vaporized or inhaled free-base DMT are 40—50 mg, although a dose may be as much as mg Shulgin and Shulgin, The onset of vaporized DMT is rapid, similar to that of i.
It is of interest to note that intranasal free-base DMT is inactive 0. There is also additional significant literature concerning the administration of DMT via consumption of ayahuasca. While of great scientific interest, this subject is not reviewed here. This is mainly due to the complexity of composition of ayahuasca, especially the presence of significant MAOI effects. Strassman et al. DMT was administered at doses of 0. The results of these studies showed peak DMT blood levels and subjective effects were attained within 2 min after drug administration and were negligible at 30 min.
Prolactin and growth hormone levels rose equally at all doses of DMT. Levels of melatonin were unaffected. The lowest dose that produced statistically significant effects relative to placebo and that was also hallucinogenic was 0. The effects observed and the biochemical and physiological parameters measured in these studies add needed insight into the role and function of endogenous DMT.
However, we must distinguish the effects of exogenously administered DMT from that which may be observed from its natural role as an endogenous substance. The concentrations actually attained in whole brain or in specific areas required to produce hallucinogenic effects from such administrations are unknown. Part of that research will require the renewal of drug administration studies to assess the many prospects that have been raised by recent and current research. Gallimore and Strassman have offered an interesting proposal regarding the future conduct of DMT administration research; a target-controlled continuous, low-dose, IV infusion.
Specifically, some of their most prominent effects occur in the prefrontal cortex—an area involved in mood, cognition, and perception—as well as other regions important in regulating arousal and physiological responses to stress and panic.
Ingesting hallucinogenic drugs can cause users to see images, hear sounds, and feel sensations that seem real but do not exist. Their effects typically begin within 20 to 90 minutes of ingestion and can last as long as 12 hours. Bad trips, however, include terrifying thoughts and nightmarish feelings of anxiety and despair that include fears of losing control, insanity, or death.
Some research has suggested that DMT occurs naturally in the human brain in small quantities, leading to the hypothesis that release of endogenous DMT may be involved in reports of alien abductions, spontaneous mystical experiences, and near-death experiences, but this remains controversial Barker, Use of hallucinogenic drugs also produces tolerance to other drugs in this class, including psilocybin and peyote. Use of classic hallucinogens does not, however, produce tolerance to drugs that do not act directly on the same brain cell receptors.
In other words, there is no cross-tolerance to drugs that act on other neurotransmitter systems, such as marijuana, amphetamines, or PCP, among others. Furthermore, tolerance for hallucinogenic drugs is short-lived—it is lost if the user stops taking the drugs for several days—and physical withdrawal symptoms are not typically experienced when chronic use is stopped.
The long-term residual psychological and cognitive effects of peyote remain poorly understood. Although one study found no evidence of psychological or cognitive deficits among Native Americans who use peyote regularly in a religious setting, those findings may not generalize to those who repeatedly abuse the drug for recreational purposes Halpern,
0コメント